Trial TCTR20210720007
Publication Niyomnaitham S, Hum Vaccin Immunother, 2022
Primary outcome on the report: A sample size of 30 per group would give 0.9 power to determine the significant difference in anti-RBD IgG based on a previous study of homologous CoronaVac and ChAdOx1

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.